Literature DB >> 16786360

[Generalized anxiety disorder with comorbidity. Treatment with pregabalin].

D Lauer1, L Hölzel, M Hornyak.   

Abstract

The efficacy of pregabalin in treating generalized anxiety disorder (GAD) has been shown in recent studies. Our experience and case reports in the present publication indicate that pregabalin can be an effective therapeutic option for patients with GAD and comorbid psychiatric disorders. Treatment with pregabalin should also be considered in patients with partial remission of GAD or intolerability of SSRI or SNRI.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16786360     DOI： 10.1007/s00115-006-2105-z

Source DB:  PubMed          Journal:  Nervenarzt        ISSN： 0028-2804            Impact factor:   1.214


  10 in total

1.  A double-blind, placebo- and positive-internal-controlled (alprazolam) investigation of the cognitive and psychomotor profile of pregabalin in healthy volunteers.

Authors:  Ian Hindmarch; Leanne Trick; Fran Ridout
Journal:  Psychopharmacology (Berl)       Date:  2005-11-09       Impact factor: 4.530

Review 2.  The epidemiology of generalized anxiety disorder in Europe.

Authors:  Roselind Lieb; Eni Becker; Carlo Altamura
Journal:  Eur Neuropsychopharmacol       Date:  2005-08       Impact factor: 4.600

Review 3.  Generalized anxiety disorder: nature and course.

Authors:  H U Wittchen; J Hoyer
Journal:  J Clin Psychiatry       Date:  2001       Impact factor: 4.384

4.  Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam.

Authors:  Karl Rickels; Mark H Pollack; Douglas E Feltner; R Bruce Lydiard; Daniel L Zimbroff; Robert J Bielski; Kathy Tobias; Jerri D Brock; Gwen L Zornberg; Atul C Pande
Journal:  Arch Gen Psychiatry       Date:  2005-09

5.  A double-blind study in healthy volunteers to assess the effects on sleep of pregabalin compared with alprazolam and placebo.

Authors:  Ian Hindmarch; Jean Dawson; Neil Stanley
Journal:  Sleep       Date:  2005-02       Impact factor: 5.849

6.  Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosing.

Authors:  Robert B Pohl; Douglas E Feltner; Ronald R Fieve; Atul C Pande
Journal:  J Clin Psychopharmacol       Date:  2005-04       Impact factor: 3.153

7.  Long-term pharmacological treatment of generalized anxiety disorder.

Authors:  V Mahe; A Balogh
Journal:  Int Clin Psychopharmacol       Date:  2000-03       Impact factor: 1.659

8.  Pregabalin in generalized anxiety disorder: a placebo-controlled trial.

Authors:  Atul C Pande; Jerri G Crockatt; Douglas E Feltner; Carol A Janney; Ward T Smith; Richard Weisler; Peter D Londborg; Robert J Bielski; Dan L Zimbroff; Jonathan R T Davidson; Maria Liu-Dumaw
Journal:  Am J Psychiatry       Date:  2003-03       Impact factor: 18.112

Review 9.  Generalized anxiety disorder and major depressive disorder comorbidity: an example of genetic pleiotropy?

Authors:  P Gorwood
Journal:  Eur Psychiatry       Date:  2004-02       Impact factor: 5.361

10.  A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder.

Authors:  Douglas E Feltner; Jerri G Crockatt; Steven J Dubovsky; Cal K Cohn; Ram K Shrivastava; Steven D Targum; Maria Liu-Dumaw; Cathryn M Carter; Atul C Pande
Journal:  J Clin Psychopharmacol       Date:  2003-06       Impact factor: 3.153
  10 in total
  1 in total

Review 1.  Current considerations in the treatment of generalized anxiety disorder.

Authors:  Martin A Katzman
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.